Ruxolitinib for first-time treatment of primary HLH
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 study tests ruxolitinib as a first treatment for primary HLH, a rare, sometimes life-threatening immune overreaction. It may help calm the immune system and improve symptoms by blocking key immune signals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 0 to 22 years.
- Your HLH must be confirmed by either a known genetic cause that can lead to primary HLH or by meeting at least 5 of several HLH warning signs (like persistent fever, enlarged spleen, and abnormal blood counts).
- You should not have had any previous specific HLH treatment before starting this study.
- You cannot have used certain prior medicines for HLH or immune control (including JAK inhibitors like ruxolitinib-type drugs, and several other immune-targeting treatments) before enrolling.
- If you can become pregnant, you must use effective birth control during the study and for a short time after the last dose; you cannot be pregnant or breastfeeding.
- You must be able to take medicines by mouth (or through a feeding tube), and you must not have major exclusions like active tuberculosis, active cancer, or severe organ failure that makes the drug unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
This study is testing a modified treatment regimen (called DEP) with or without the drug ruxolitinib for patients with HLH, a serious condition where the immune system attacks the body. The goal is to see if this combination is safe and helps control the disease.
Hear when a new Haemophagocytic Lymphohistiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.